As we move forwards in public discussions on pharmaceutical innovation and its value to patients and society, it is helpful to ground conversations in a solid understanding of how medicines development occurs.
CRA’s Life Sciences Practice team along with experts at The Janssen Pharmaceutical Companies of Johnson & Johnson recently conducted a landscape review of how complex pharmaceutical innovation happens in practice, leveraging three therapy area case studies: HIV/AIDS, multiple sclerosis, and multiple myeloma. This article is the first of two parts.
